- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
- Interventions
- BBI-355, Erlotinib, Futibatinib, BBI-825
- Drug
- Lead sponsor
- Boundless Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- AC430
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Respiratory Tract Infections
- Interventions
- RD19
- Device
- Lead sponsor
- EmitBio Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
- Interventions
- IPN01194
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more
- Conditions
- Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma, Primary Peritoneal Carcinoma
- Interventions
- ETX-929 dose escalation, ETX-929 dose escalation in combination with cetuximab
- Drug
- Lead sponsor
- Ensem Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Solid Malignant Tumor
- Interventions
- TVB-2640
- Drug
- Lead sponsor
- Sagimet Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
- Conditions
- Hematological Malignancies
- Interventions
- Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more
- Conditions
- Advanced Solid Cancer, Metastatic Solid Cancer
- Interventions
- BI 3819026, Ezabenlimab (BI 754091)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Hackensack, New Jersey • New York, New York + 1 more
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
- Interventions
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Drug
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more
- Conditions
- Healthy Subjects
- Interventions
- GSK706769
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Solid Tumor, BRAF V600 Mutation
- Interventions
- ABM-1310, Cobimetinib
- Drug
- Lead sponsor
- ABM Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- San Francisco, California • Stanford, California • Miami, Florida + 4 more
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- VX-668, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
- Interventions
- HWK-007
- Drug
- Lead sponsor
- Whitehawk Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more
- Conditions
- Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
- Interventions
- Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Atopic Dermatitis
- Interventions
- RPT193, Placebo
- Drug
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
- Conditions
- Advanced Solid Tumors
- Interventions
- BAY3375968, Pembrolizumab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more
- Conditions
- Neurogenic Detrusor Overactivity, Spinal Cord Injuries
- Interventions
- EG110A
- Drug
- Lead sponsor
- Cyllene Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Downey, California • Ann Arbor, Michigan • Columbus, Ohio + 2 more
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
- Interventions
- ELI-002 2P
- Drug
- Lead sponsor
- Elicio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Community-acquired Pneumonia, Bacterial Pneumonia
- Interventions
- CMTX-101, Placebo
- Drug
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
- Conditions
- Locally Advanced or Metastatic HER2-Expressing Cancers
- Interventions
- VIR-5818, pembrolizumab
- Drug
- Lead sponsor
- Vir Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Duarte, California • Palo Alto, California
- Conditions
- Intervention for Nerve Agent Exposure
- Interventions
- Protexia
- Biological
- Lead sponsor
- PharmAthene, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
- Interventions
- (R)-9bMS
- Drug
- Lead sponsor
- TechnoGenesys, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Interventions
- SAR443579
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
- Conditions
- Neuropathic Pain From Lumbosacral Radiculopathy
- Interventions
- KLS-2031, Placebo
- Drug · Other
- Lead sponsor
- Kolon Life Science
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah